SCHEMBL761827

SCHEMBL761827

CC1=NN(C)Cc2ccccc2C1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.41
MAPT P10636 3/20 0.41
DRD3 P35462 3/20 0.41
DRD1 P21728 3/20 0.41
DRD5 P21918 3/20 0.41
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41
DRD2 P14416 2/20 0.41
DRD4 P21917 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.38
HPGD P15428 1/20 0.38
GAA P10253 3/20 0.38
CYP1A2 P05177 3/20 0.38
KDM4E B2RXH2 2/20 0.38
KMT2A Q03164 2/20 0.38
MEN1 O00255 1/20 0.38
CHRM2 P08172 1/20 0.38
CYP3A4 P08684 1/20 0.38
CHRM1 P11229 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL762714 0.72 ALDH1A1 (0.38) ALDH1A1MAPTDRD3DRD1DRD5
SCHEMBL761635 0.72 NPC1 (0.40) ALDH1A1MAPTDRD3DRD1MAOA
SCHEMBL24227957 0.69 DRD1 (0.62) DRD3DRD1DRD5MAOAMAOB
SCHEMBL17559143 0.67 HSD11B1 (0.40) ALDH1A1MAPTDRD3DRD1MAOA
SCHEMBL11914735 0.66 TSHR (0.39) ALDH1A1MAPTDRD3DRD1DRD5
SCHEMBL13347978 0.65 ALOX15 (0.41) ALDH1A1MAPTDRD3DRD1DRD5
SCHEMBL14573056 0.65 MAOA (0.56) ALDH1A1MAPTDRD3DRD1DRD5
SCHEMBL130712 0.65 MAOA (0.71) ALDH1A1MAPTDRD3DRD1DRD5
SCHEMBL10745421 0.64 IDO1 (0.42) ALDH1A1MAPTDRD3DRD1MAOA
SCHEMBL1490708 0.64 MAOA (0.40) ALDH1A1DRD3DRD1DRD5MAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8138182-B2 Diketohydrazine derivative compounds and drugs containing the compounds as the active ingredient ONO PHARMACEUTICAL CO., LTD. (JP) 2012-03-20 US disclosed
US-20100087442-A1 DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD (JP) 2010-04-08 US disclosed
US-7655804-B2 N-[(1S)-3-{(2Z)-2-[(4R)-3,4-dimethyl-1,3-thiazolidin-2-ylidene]hydrazino}-2,3-dioxo-1-(tetrahydro-2H-pyran-4-yl)propyl]cycloheptanecarboxamide; cysteine protease inhibitors; for the treatment of inflammatory, immune, ischemic, respiratory,circulatory, neuronal, blood, hepatic and metabolic diseases ONO PHARMACEUTICAL CO., LTD. (JP) 2010-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087442-A1 DIKETOHYDRAZINE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THE COMPOUNDS AS THE ACTIVE INGREDIENT SERPINB1, CTSZ, ELANE ALDH1A1 481/4885MAPT 1609/4885DRD3 2473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.